ABSTRACT: Radiolabeled bombesin (BBN) analogs have long been used for developing gastrin-releasing peptide receptor (GRPR) targeted imaging probes, and tracers with excellent in vivo performance including high tumor uptake, high contrast, and favorable pharmacokinetics are highly desired. In this study, we compared the 68 Ga-labeled GRPR agonist (Gln−Trp−Ala−Val−Gly−His−Leu−Met−NH 2 ,
■ INTRODUCTION
Prostate cancer (PCa) accounts for almost 20% of the newly diagnosed cancers among men in the United States in 2017 and remains the third-leading cause of cancer related male death. 1 A typical diagnosis of PCa relies on the histopathological examination of suspected prostate biopsy tissues or specimens from benign prostatic enlargement surgeries or transurethral resection of the prostate following the detection of elevated prostate-specific antigen (PSA) levels, abnormal digital rectal examination (DRE), bone scanning, or a combination of all three. X-ray computed tomography and magnetic resonance imaging (MRI) are currently the major imaging techniques for further identification of PCa. 2 However, the capacity of conventional diagnostic techniques for primary lesion detection, staging, or relapse monitoring of PCa is limited. 3 For example, the PSA test can be interfered by noncancerous factors such as prostate enlargement, old age, and prostatitis, and low levels of PSA do not necessarily rule out the incidence of PCa. 4 The sensitivity and specificity of either ultrasound or MRI is also limited by abnormal signals confounded by prostatitis or benign prostatic hyperplasia (BPH). 5, 6 The notable multiparametric MRI (MP-MRI) remains imperfect as well, with a pooled sensitivity of up to 89% and a specificity of up to 73%. 7 Interest in applying molecular imaging to positron emission tomography (PET) has grown, and a plethora of radiotracers have been developed and investigated actively for PCa. The classical 2-deoxy-2- 18 F-fluoro-D-glucose ( 18 F-FDG) has been used for evaluating late-stage or recurrent PCa but is not particularly avid. 8, 9 Other promising agents targeting metabo-lites such as fatty acids and amino acids (e.g., 11 C-and 18 Fcholine, 11 C-acetate, and 18 F-FACBC) have been further introduced 3, 10 as well as agents targeting specific PCa antigens such as prostate-specific membrane antigen (PSMA). 11, 12 These tracers are proven beneficial for recurrent PC diagnosis and staging. The PSMA targeted tracers have also been applied specially for predicting the optimal timing of PSMA-based therapies. 13 However, almost all these tracers show limited diagnostic accuracy for primary lesions, 3, 10, 14 and few of those tracers have been sufficiently investigated and clinically validated to date.
The gastrin-releasing peptide receptor (GRPR) is a G protein-coupled receptor expressed in various organs of mammals, especially in the gastrointestinal tract and the pancreas. Upon binding with the ligand gastrin-releasing peptide (GRP), GRPR can be activated and elicit certain exocrine or endocrine secretions to regulate multiple physiological processes. 15 Notably, GRPR over-expression is presented in several types of tumors such as prostate, urinary tract, gastrointestinal stromal, breast, and lung and is related to proliferation and growth of these malignancies. 16, 17 Especially, GRPR is almost 100% expressed in clinical PCa samples investigated by PCR, immunohistochemistry, or radionuclide binding assays, 16 which makes GRPR an attractive target for PCa imaging and therapy.
As an amphibian homologue of GRP, bombesin (BBN) was found to bind to GRPR with a high affinity. For decades, the BBN motifs have been used extensively in radioactive imaging or in radionuclide therapy for GRPR-over-expressing cancers. 18, 19 For example, the GRPR agonist BBN 7−14 , a truncated form of BBN with the sequence of Gln−Trp−Ala−Val−Gly− His−Leu−Met−NH 2 , has been studied as PET or single photon emission computed tomography (SPECT) tracers in both preclinical and clinical research. 20−23 In the meantime, numerous clinical trials have been performed using antagonistic GRPR targeting PET radiopharmaceuticals including 68 Ga− RM2, 24,25 68 Ga−SB3, 26 68 Ga−BAY86−7458, 27 and 64 Cu−CB− TE2A−AR06. 28 Recently, a nine-amino-acid analog of nonapeptide BBN 6−14 , D-Phe−Gln−Trp−Ala−Val−Gly−His−Sta− Leu−NH 2 (RM26) has been developed as an antagonist against GRPR and has been applied actively in preclinical studies. 29−32 Based on these observations, both BBN 7−14 and RM26 are considered high-quality candidates for further clinical translation.
Despite the outstanding tumor targeting potential, BBN related research is accompanied by a debate on the superiority of GRPR antagonist-versus agonist-based tracers. 33−36 It is generally claimed that even though antagonists are not internalized, radiolabeled antagonists may depict clearer images and pharmacokinetic profiles than agonists. More data are expected to emerge for direct comparison of specific radiolabeled agonist and antagonist tracers to address this controversy, especially among tracers that are promising for clinical translation.
Herein, we establish the distinction of GRPR targeted agonist and antagonist with similar sequences by applying 68 Ga-labeled BBN 7−14 and RM26 for side-by-side comparative studies, including in vitro receptor binding, cell uptake, internalization, and efflux studies on PC-3 cells and in vivo microPET imaging study of PC-3 tumor bearing mice. The in vitro and in vivo stabilities of both radio conjugates were presented and compared as well. Ga− NOTA−PEG 3 −RM26, and for both, radiochemical yield was >90−95% and radiochemical purity was >98%. The chemical structures of 68 Ga−NOTA−Aca−BBN 7−14 and 68 Ga−NOTA− PEG 3 −RM26 were presented in Figure 1 .
In Vitro Stability. In vitro stabilities of 68 Ga−NOTA− Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26 in saline and nonheat-inactivated fetal bovine serum (FBS) (Gibco) were determined according to peak integration of analytical highperformance liquid chromatography (HPLC). At 0 min of the incubation, the radiochemical purities of 68 Ga−NOTA−Aca− BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26 were all >95% in both saline and FBS (Figure 2) . After 2 h of incubation, the parent compound of 68 Ga−NOTA−Aca−BBN 7−14 in saline dropped to 88.42% along with a more-hydrophilic peak of 11.58%, while this metabolism for 68 Ga−NOTA−Aca− BBN 7−14 incubated in FBS was not as obvious. Metabolites represented by radio peaks of slightly higher lipophilicity than the parent compounds were observed for both after 2 h incubation in FBS, accompanied by the percentages of the parent compounds dropping to 89.24% and 80.58%, Figure 1 . Schematic structures of (A) GRPR agonist 68 Ga−NOTA− Aca−BBN 7−14 and (B) antagonist 68 Ga−NOTA−PEG 3 −RM26.
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Article respectively, for 68 7−14 , and NOTA−PEG 3 −RM26 were 0.32 ± 0.10, 0. 41 ± 0.13, 1.80 ± 0.67, and 2.05 ± 0.50 nM, respectively. The results indicated that the intermolecular targeting abilities of BBN 7−14 and PEG 3 −RM26 for GRPR were comparable. After the NOTA conjugation, the affinities of both compounds decreased to some extent. However, there were no distinct disparities discovered between NOTA−Aca−BBN 7−14 and NOTA−PEG 3 −RM26, either.
Cell Uptake, Internalization, and Efflux. A timedependent cellular-uptake pattern in GRPR positive PC-3 cells was observed for both 68 Ga−NOTA−Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26. The uptake of 68 Ga−NOTA− Aca−BBN 7−14 increased rapidly to nearly 27% within 1 h of incubation, and that of 68 Ga−NOTA−PEG 3 −RM26 was slightly lower ( Figure 4A ). The agonist 68 Ga−NOTA−Aca− BBN 7−14 showed distinctively high internalization, and around 74% of the radioactivity uptake was internalized within 1 h of incubation. In contrast, 68 Ga−NOTA−PEG 3 −RM26 showed very low internalization (<15% of total uptake; Figure 4A ). After washing and medium replacement, both of the tracers showed efflux with a similar pattern ( Figure 4B ). At 60 min, 50% of radioactivity uptake was still retained with the cells.
In Vivo PET Imaging. Representative coronal PET images of PC-3 tumor-bearing mice at different time points are shown in Figure 5 . The tumors were clearly visualized with high contrast at all the time points for 68 Ga−NOTA−PEG 3 −RM26 (n = 3) as well as at 15 and 30 min for 68 Ga−NOTA−Aca− BBN 7−14 (n = 4). However, at 60 min post-injection, the tumor became much less visible in the mice administered with 68 Ga− NOTA−Aca−BBN 7−14 ( Figure 5A ). Meanwhile, both of the 
Article tracers showed considerable accumulation and retention in the abdominal regions including pancreas and intestines, although less was observed for 68 Ga−NOTA−PEG 3 −RM26 than for 68 Ga−NOTA−Aca−BBN 7−14 . At these early time points, relatively high kidney radioactivity was observed while the radioactivity in the bladder was constantly high for these two probes, suggesting that the tracers were excreted mainly by the renal system. Activity accumulation in the tumor was quantified by measuring the regions of interest (ROIs) on the coronal images ( Figure 5B ,C). The mean tumor uptake was determined to be 4.40 ± 0.29, 3.28 ± 0.47, and 2.04 ± 0.34 percentage of injected dose per gram of tissue (%ID/g) for 68 Ga−NOTA− Aca−BBN 7−14 , and 2.99 ± 0.44, 2.96 ± 0.45, and 3.01 ± 0.45% ID/g for 68 Ga−NOTA−PEG 3 −RM26 at 15, 30, and 60 min, with the corresponding P values of <0.01, 0.39, and 0.02, respectively, when comparing tumor uptake of the two tracers at the same time points post-injection.
However, the maximum tumor uptake was determined to be 6.68 ± 0.69, 5.14 ± 1.15, and 4.77 ± 0.96%ID/g for 68 Ga− NOTA−Aca−BBN 7−14 , and 4.96 ± 0.87, 4.79 ± 0.98, and 4.91 ± 1.00%ID/g for 68 Ga−NOTA−PEG 3 −RM26 at 15, 30, and 60 min, with the corresponding P values of 0.03, 0.68, and 0.85, respectively, when comparing the tumor uptake of the two tracers at the same time points post-injection.
Biodistribution of 68 Ga−NOTA−Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26. The biodistribution of 68 Ga− NOTA−Aca−BBN 7−14 (n = 4) and 68 Ga−NOTA−PEG 3 − RM26 (n = 3) in tumor and normal tissues determined by γ-counting was presented in Figure 6A . In good agreement with the PET images, high uptake and long retention of the radioactivity were observed for the GRPR-positive tissues including pancreas, intestine, and PC-3 tumor at 60 min postinjection, which were 17.99 ± 1.48, 4.33 ± 1.90, and 2.40 ± 0.38 ID/g for 68 Ga−NOTA−Aca−BBN 7−14 and 9.51 ± 0.73, 0.93 ± 0.12, and 3.31 ± 0.68%ID/g for 68 Ga−NOTA−PEG 3 − RM26.
However, the tumor-to-lung, tumor-to-liver, tumor-tokidney, tumor-to-pancreas, tumor-to-intestine, and tumor-tomuscle ratios for the radiopharmaceuticals at 1 h post-injection were shown in Figure 6B , which were 2.66, 9.66, 3.22, 0.34, 3.69, and 72.5 for 68 Ga−NOTA−PEG 3 −RM26 and 5.34, 3.15, 1.52, 0.13. 0.56, and 25.57 for 68 Ga−NOTA−Aca−BBN 7−14 , respectively. Except for the tumor-to-lung uptake ratios, 68 Ga− NOTA−PEG 3 −RM26 showed much better tumor-to-organ contrast than that of 68 Ga−NOTA−Aca−BBN 7−14 (P values of <0.01 and <0.05). Specially, the tumor-to-muscle ratio of 68 Ga−NOTA−Aca− BBN 7−14 (n = 4, mean ± SD) and 68 Ga−NOTA−PEG 3 −RM26 (n = 3, mean ± SD), expressed as %ID/g_mean. (C) PET quantification of tumor uptake in PC-3 tumors 15, 30, and 60 min after the injection of 68 Ga−NOTA−Aca−BBN 7−14 (n = 4, mean ± SD) and 68 Ga−NOTA−PEG 3 −RM26 (n = 3, mean ± SD), expressed as %ID/g_max.
Article 68 Ga−NOTA−PEG 3 −RM26 was 2.88-fold of that of the radioagonist.
In Vivo Stability of 68 Ga−NOTA−Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26. The in vivo metabolic stabilities of the radio conjugates were determined in each sample of mouse serum at 5 min after injection and in urine and tumor homogenates at 30 min after injection (Figure 7) . The average extraction efficiencies were 89.3%, 97%, and 84.2% for serum, urine, and tumor, respectively. The composition of the metabolites was not identified, and almost all of the metabolites came earlier off the HPLC column than the parent compound for 68 Ga−NOTA−Aca−BBN 7−14, but the 68 Ga-NOTA-PEG 3 -RM26 profile revealed a radio-metabolite with slightly higher lipophilicity that came off of the column after the parent compound. At 5 min post-injection, almost no parent form of 68 Ga−NOTA−Aca−BBN 7−14 was found in serum ( Figure 7A) ; however, 88.92% of 68 Ga−NOTA−PEG 3 −RM26 remained intact at the same time point ( Figure 7B ). In tumor, about 28.53% for 68 Ga−NOTA−Aca−BBN 7−14 ( Figure 7C ) and 79.74% for 68 Ga−NOTA−PEG 3 −RM26 ( Figure 7D ) were intact. In urine, no parent form of either probe was observed ( Figure 7E,F) .
■ DISCUSSION BBN analogues have been widely labeled with radionuclides such as 68 Ga, 64 Cu, 18 F, and 177 Lu. 8, 20, 22, 23, 37 In particular, 68 Ga can be easily produced due to the availability and commercialization of the in-house 68 Ge and 68 Ga generators ( 68 Ge, t 1/2 = 270.8 days). The 68 Ga-labeling of BBN derivatives conjugates come with high labeling yield, satisfactory radiochemical purity, and specific activity, and the clinical implementation of 68 Ga radiopharmaceuticals is preferred in the routine clinical setup of nuclear medicine. In this study, both BBN-based probes were prepared with high radiochemical purity and specific activity within 20 min, demonstrating ideal radiochemical processing for clinical translation.
In this study, we synthesized the NOTA-conjugated GRPR agonist BBN 7−14 and antagonist RM26; PEG 3 was used as a linker to conjugate NOTA to the antagonist peptide. The IC 50 values of NOTA−Aca−BBN 7−14 and NOTA−PEG 3 −RM26 were similar to each other and also close to analogs reported from other laboratories previously. 31, 33 Despite similar binding affinities, the tumor uptake of 68 Ga−NOTA−Aca−BBN 7−14 dropped rapidly from 4.40%ID/g at 15 min to 2.04%ID/g at 60 min post-injection in our study, and that of 68 Ga−NOTA− PEG 3 −RM26 remained at a plateau of around 3.00%ID/g. The declining pattern of tumor uptake for 64 Cu-NOTA−Aca− BBN 7−14 in PC-3 tumor mice from 1 to 24 h post-injection has also been reported previously, and the authors speculate that the signal decrease was primarily due to rapid clearance from the bloodstream and excretion via the renal-urinary pathway.
22
Both 68 Ga−NOTA−Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 − RM26 were mainly excreted through the urinary tract, so high accumulation of radioactivity in the bladder was observed. However, the kidney uptake was moderate compared with other peptide-based tracers. 38 Consistently, we observed most of 68 Ga−NOTA−PEG 3 −RM26 in mouse serum remained intact at 5 min after injection, in comparison to 3.16% of 68 Ga− NOTA−Aca−BBN 7−14 , indicating much greater metabolic stability in vivo for the antagonist and better suitability for GRPR imaging of 68 Ga−NOTA−PEG 3 −RM26. In agreement with the PET imaging study, the ex vivo biodistribution results further validated higher tumor-to-organ ratios for 68 Ga−NOTA−PEG 3 −RM26 in comparison with those of 68 Ga−NOTA−Aca−BBN 7−14 at 60 min after injection. Hence, the higher tumor uptake and lower background offer 68 Ga−NOTA−PEG 3 −RM26 more sensitivity in detecting indistinct lesions, such as metastasis distributed in the abdominal area in clinical settings.
It is well-known that introduction of different linkers between the metal chelator and targeting peptide sequence results in different tumor uptake and distinct normal organ distribution.
39,40 Indeed, we have included 68 Ga−NOTA− PEG 3 −Aca-BBN 7−14 in the experimental design for this comparison study. However, both PET imaging and biodistribution results revealed that 68 Ga−NOTA−PEG 3 −Aca-BBN 7−14 was the worst probe compared with the other two probes. The results indicated that the PEG 3 modification itself did not substantially alter the in vivo pharmacokinetics of BBN 7−14 , and the difference between 68 Ga−NOTA−Aca− BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26 mainly came from the inherent distinction of the peptide sequences and the agonism and antagonism of the two probes.
For in vitro stability assay, a minor portion of relatively hydrophilic radio peak was observed for 68 Ga−NOTA−Aca− Figure 6 . Biodistribution of 68 Ga−NOTA−Aca−BBN 7−14 (blue bars, n = 4) and 68 Ga−NOTA−PEG 3 −RM26 (red bars, n = 3) in PC-3 tumor bearing nude mice at 60 min after administration (mean ± SD). (A) Biodistribution of 68 Ga−NOTA−Aca−BBN 7−14 and 68 Ga− NOTA−PEG 3 −RM26 in multiple organs of PC-3 tumor bearing nude mice. Significant differences (P < 0.05) in biodistribution between probes were marked with asterisks. (B) Comparative ratios of the tumor uptake to major organs for 68 Ga−NOTA−Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26 at 1 h post-injection. Significant differences (P values of <0.01 and <0.05) in tumor-to-organ ratios between probes were marked with asterisks.
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Article BBN 7−14 incubated in saline, which could result from radiolysis of the Met residue of 68 Ga−NOTA−Aca−BBN 7−14 , while in FBS incubation, this kind of decomposition was possibly suppressed by the presence of serum proteins. 41, 42 Moreover, a slightly more lipophilic radio peak was observed after 120 min incubation in nonheat inactivated FBS for both 68 Ga−NOTA− Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26, each consisting 10.76% and 19.42% of the radiopharmaceuticals. Formation of these metabolites may have been derived from the action of serum proteases in nonheat inactivated FBS such as carboxamidase, which could catalyze the hydrolysis of Cterminal carboxamides to the corresponding carboxy acid. 43 In vivo stability assay via radio-HPLC also indicated better stability of 68 Ga−NOTA−PEG 3 −RM26 compared to 68 Ga− NOTA−Aca−BBN 7−14 in tumor homogenates. However, the structure of the radioactive fragments was not identified because the mass amount for the injection was limited. In a previous study, we observed a rapid degradation of BBN 7−14 during incubation in rat hepatocytes (t 1/2 = 4 min), and the metabolites of BBN 7−14 were found to be derived from peptide bond hydrolysis between amino acids Trp and Ala and between Ala and Val and within the C-terminal amide by high-resolution mass spectrometry coupled with HPLC (LC−MS). 44 Nevertheless, in vitro study does not necessarily represent the situation encountered by intravenously administered radiopeptides in vivo. Indeed, using in vivo mouse plasma metabolized fragment of 177 Lu−AMBA, the weak sites were revealed within the backbone of BBN 7−14 between amino acids Gln and Trp, Trp and Ala, and His and Leu, as well as the terminal amide of 177 Lu−AMBA. 43 It has been proposed and confirmed that neutral endopeptidase (NEP) acts as the major protease in the degradation of bombesin-like radiopeptides in vivo and that the co-injection of NEP inhibitors could enhance stability and tumor uptake of those radiopeptides. 45−47 It is worth pointing out that a lack of stability is not an inherent issue for all GRPR agonists. Through structural interventions including peptide chain-length modification, amino acid substitutions, application of an amide-to-triazole replacement strategy, or the introduction of different lengths of spacer bridging the chelator to the peptide receptor-recognition site, the biological profiles (especially of radioligand pharmacokinetics in vivo) could be significantly improved. 45 ,48−50 The major hindrance of GRPR agonists is the possible biological effect induced upon receptor binding when a large amount of the agonists is administered for therapeutic purpose. A morestable GRPR agonist may be still meaningful as an imaging probe.
■ CONCLUSIONS
The antagonist-based probe 68 Ga−NOTA−PEG 3 −RM26 showed higher tumor uptake with lower background in the PC-3 tumor bearing mouse model at 1 h post-injection and displayed more-favorable in vivo pharmacokinetic properties as well as metabolic stabilities. 68 Ga−NOTA−PEG 3 −RM26 is, therefore, a more-promising candidate for clinical translation of PET imaging for PCa compared to the agonist 68 Ga−NOTA− Aca−BBN 7−14 .
■ MATERIALS AND METHODS
Chemistry. Aminocaproic acid (Aca)−BBN 7−14 and RM26 were synthesized using solid-phase Fmoc chemistry by Peptides International Inc. and CSBio. 1,4,7-Triazacyclononane-1,4,7-triacetic acid N-hydroxysuccinimide (NOTA−NHS) ester was purchased from CheMatech (Dijon, France). All other chemicals were obtained from Sigma-Aldrich. NOTA−Aca− BBN 7−14 and NOTA−PEG 3 −RM26 were prepared according to a procedure published previously. 
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Article 68 Ga was eluted from a 68 Ge and 68 Ga generator (ITG) with 0.6 M HCl at 0.5 mL per fraction. A total of 0.5 mL of 1 M HEPES buffer was added to the fraction containing the most amount of 68 Ga radioactivity (185−222 MBq) to a final pH of around 6.0. A total of 10 μg of NOTA−Aca−BBN 7−14 or NOTA−PEG 3 −RM26 in 10 μL of water was added to the above solution. After shaking, the mixture was incubated at 80°C for 10 min. The reaction mixture was trapped on an activated Varian Bond Elut C18 column (100 mg) by a syringe. Another 10 mL of water was used to wash the column, followed by 0.3 mL of 1 mM HCl ethanol solution to elute off the trapped radioactivity. Next, the product was diluted with saline for further use. An analytical reverse-phase radio HPLC (Waters Symmetry C-18 column, 3.9 × 150 mm, 5 μm) running a linear gradient starting from 5% A (0.1% TFA in acetonitrile) and 95% B (0.1% TFA in water) for 5 min and A increased to 65% at 2% per min, with the flow rate of 1 mL/ min used for characterization of both tracers and in vitro and in vivo stability analysis.
In Vitro stability Test. The in vitro stability of 68 Ga− NOTA−Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26 was examined by radio HPLC according to a procedure reported previously. 51 Briefly, about 37 kilobecquerel (KBq) of 68 Ga− NOTA−Aca−BBN 7−14 (40.0 MBq/nmol) or 68 Ga−NOTA− PEG 3 −RM26 (39.8 MBq/nmol) in 50 μL was incubated in 450 μL of normal saline or FBS at 37°C. At 0 and 120 min incubation, 25 μL of the saline-incubated sample was taken out of the tube and subjected to HPLC analysis. However, 25 μL of the serum sample was taken out at the same time points, added to an equal volume of acetonitrile, and centrifuged at 6000 rpm for 10 min. The supernatant was then extracted and submitted for radio-HPLC analysis.
Cell Culture and Animal Models. The PC-3 human prostate carcinoma cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD). The cells were grown in Roswell Park Memorial Institute (RPMI) 1640 Medium supplemented with 10% FBS, penicillin (100 IU/mL), and streptomycin (100 mg/mL) (Invitrogen, Carlsbad, CA) and cultured at 37°C in a humidified atmosphere containing 5% CO 2 . Cells were passaged three times per week.
All animal studies were conducted according to the principles and procedures outlined in the Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the Clinical Center, National Institutes of Health (NIH). Female BALB/c mice (age, 5−7 weeks; weights of 18−20 g) and female athymic nude/nude mice (age, 5−7 weeks; weights of 18−20 g) were purchased from Harlan Laboratories.
The PC-3 tumor models were generated by subcutaneous injection of 5 × 10 6 cells into the right shoulder of nude mice. Tumor sizes were measured using a digital caliper. Tumor volume (mm 3 ) was calculated according to the formula 0.5 × length × width 2 . The mice were subjected to micro PET studies when the tumor volume reached 100−300 mm 3 (3−4 weeks after inoculation).
In Vitro Cell Receptor Binding Assay. In vitro GRPRbinding affinities and specificities of BBN 7−14 , PEG 3 -RM26, NOTA−Aca−BBN 7−14 , and NOTA−PEG 3 −RM26 were determined by displacement PC-3 cell-binding assays using 125 68 Ga− NOTA−Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26) were added in 0.5 mL of serum-free media (SFM). The cells were incubated at 37°C for 5, 15, 30, and 60 min. At each indicated time point, the medium was removed, and cells were rinsed twice with cold PBS (1 mL) and lysed by the addition of 0.2 mL of 0.1 M NaOH. The cell lysate was collected for γ-counting. For internalization study, after the removal of the medium at the same indicated time point as the cell uptake study, the cells were incubated for 1 min with 0.5 mL of acid buffer (50 mM glycine and 100 mM NaCl at pH 2.8). Next, the acid buffer was removed, and the cells were washed twice with 1 mL of PBS, followed by addition of 0.2 mL of 0.1 M NaOH. Cell lysate was collected, and the radioactivity was measured by a γ-counter. The cell uptake and internalization values were normalized to the amount of added radioactivity. Each experiment was performed in triplicate.
Cell Efflux Studies. For a cell-efflux study of 68 Ga− NOTA−Aca−BBN 7−14 (39.8 MBq/nmol)and 68 Ga−NOTA− PEG 3 −RM26 (52.5 MBq/nmol), 7.4 KBq per well of tracers were added to PC-3 cells in a 24-well plate and incubated for 1 h at 37°C. Next, cells were washed twice with cold PBS and incubated with SFM for 5, 15, 30, and 60 min. After being washed twice with PBS, cells were harvested by the addition of 0.2 mL of 0.1 mol/L NaOH. Cell lysate was collected and the radioactivity measured by a γ-counter. Efflux values were calculated by subtracting retention at different time points from 0 min retention and normalized by dividing the total counts at 0 min.
PET of Tumor-Bearing Mice. PET scans were obtained using an Inveon small animal PET scanner (Siemens Medical Solutions). Under isoflurane anesthesia, 5 min of static PET scanning was performed at 15, 30, and 60 min after the PC-3 tumor-bearing mice were each intravenously injected with 3.7 MBq of 68 Ga−NOTA−Aca−BBN 7−14 (28.2 MBq/nmol) (n = 4) or 68 Ga−NOTA−PEG 3 −RM26 (32.6 MBq/nmol) (n = 3) in a volume of 100 μL of PBS.
The PET images were reconstructed using 3-dimensional ordered-subsets expectation maximum (3D OSEM) followed by maximum a posteriori (MAP) algorithm with a smoothing parameter (OSEM-3D-MAP) of 0.1. For each scan, regions of interest (ROIs) were drawn over the tumor on whole-body decay-corrected coronal images using vendor software (ASI Pro 5.2.4.0; Siemens Medical Solutions). The radioactivity accu-
Article mulation within the tumor was calculated from mean pixel values of the multiple ROI volumes. These values were converted to MBq/mL and then further divided by the administered activity to obtain an image-ROI-derived %ID/g value (assuming a tissue density of 1 g/mL). No correction was applied in this study.
Biodistribution of 68 Ga−NOTA−Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26. Each mouse was intravenously injected with 3.7 MBq of 68 Ga−NOTA−Aca−BBN 7−14 (28.2 MBq/nmol) (n = 4) or 68 Ga−NOTA−PEG 3 −RM26 (32.6 MBq/nmol) (n = 3) in a volume of 100 μL of PBS. At 1 h postinjection, the mice were sacrificed, and blood, heart, liver, kidneys, spleen, bone, muscle, tumor, intestine, pancreas, and lung tissues were collected. The organs were wet-weighed, and the radioactivity was assayed using a γ-counter.
In Vivo Stability of 68 Ga−NOTA−Aca−BBN 7−14 and 68 Ga−NOTA−PEG3−RM26. For serum metabolic stability studies, each healthy Balb/c mouse was injected intravenously with 37 MBq of 68 Ga−NOTA−Aca−BBN 7−14 (34.9 MBq/ nmol) or 68 Ga−NOTA−PEG 3 −RM26 (46.8 MBq/nmol). At 5 min after injection, the mice were anesthetized, and 100 μL of blood was collected. The blood sample was immediately centrifuged at 13 200 rpm for 5 min. A total of 25 μL of the supernatant was removed and mixed with an equal volume of acetonitrile, with centrifugation at 6000 rpm for 10 min. Next, the extracted solution was injected into an HPLC device for analysis. For urine analysis, the urine was collected at 30 min post-injection, and then 25 μL of the urine was mixed with an equal volume of acetonitrile and centrifuged at 13 200 rpm for 5 min. The supernatant was moved and subjected to HPLC analysis.
For tumor metabolism analysis, a pair of PC-3 tumor bearing mice were injected with 37 MBq of each tracer (with the specific activities of 32.9 and 31.6 MBq/nmol for of 68 Ga− NOTA−Aca−BBN 7−14 and 68 Ga−NOTA−PEG 3 −RM26, respectively). At 30 min after injection, the mice were sacrificed under anesthesia, and the tumors were removed and weighed. With an equal weight of acetonitrile, the tumor was homogenized on ice and centrifuged at 13 200 rpm for 5 min. A total of 50 μL of the supernatant was removed for HPLC analysis.
The radioactivity of in vivo collected blood, urine, and tumor samples was measured with a γ-counter each time before and after the samples were homogenized or centrifuged to calculate the extraction efficiency. All samples were collected in prechilled vials, and all further manipulations were conducted on ice or at 4°C for centrifugation to prevent further degradation during sample workup.
Statistical Analysis. All quantitative data are presented as mean ± SD. Mean values were compared using one-way ANOVA and the Student t test. P values of <0.05 were considered statistically significant.
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